Incidence, causes, and timing of peripheral intravenous catheter failure related to insertion timing in the treatment cycle in patients with hematological malignancies: A prospective descriptive study
Incidence, causes, and timing of peripheral intravenous catheter failure related to insertion timing in the treatment cycle in patients with hematological malignancies: A prospective descriptive study
复制标题
血液恶性肿瘤患者治疗周期中与插入时间相关的外周静脉导管失败的发生率、原因和时间：一项前瞻性描述性研究
DOI：
10.1111/jjns.12484
复制
发表时间：
2022
影响因子：
1.7
通讯作者：
Sanada Hiromi
中科院分区：
文献类型：
--
作者：
Shintani Yui;Murayama Ryoko;Abe‐Doi Mari;Sanada Hiromi
AimWe旨在揭示在淋巴瘤、白血病和骨髓瘤患者治疗周期中与插入时间相关的外周静脉导管（PIVC）失败的详细描述性数据。方法我们进行了一项前瞻性描述性研究，以调查PIVC失败的发生率，定义为在完成输液治疗之前PIVC移除。这是由需要PIVC植入化疗的成人患者的病房护士判断的。一名研究护士通过超声显像确定了PIVC失败的时间和原因。描述性数据收集于日本一家三级医院的血液学和肿瘤学病房。结果共纳入85例患者（303例），分析67例患者（280例）。其中，118例（42%）在治疗周期的化疗给药期间插入，106例（38%）在休息期间插入。累积PIVC失败的发生率为43.2% （89.97 / 1000 PIVC天）。在淋巴瘤患者的PIVC中，在给药期间插入的PIVC失败的可能性较小（32%对57%，p< 0.001）。相反，在治疗周期后插入的患者更有可能出现PIVC失败（22%对7%，p= 0.002）。结论血液学恶性肿瘤患者PIVC衰竭的发生率高得不可接受。可以想象，PIVC失败的发生率随治疗周期中副作用的发生时间而变化。在使用pivc和为血液系统恶性肿瘤患者选择最佳血管通路装置时应考虑到这一点。
AimWe aimed to reveal detailed descriptive data on peripheral intravenous catheter (PIVC) failure related to insertion timing during the treatment cycle, in patients with lymphoma, leukemia, and myeloma.MethodsWe conducted a prospective descriptive study to investigate the incidence of PIVC failure, defined as PIVC removal prior to completing infusion therapy. This was judged by ward nurses for adult patients requiring PIVC insertion for chemotherapy. A research nurse confirmed the timing and determined the causes of PIVC failure using ultrasonographic imaging. Descriptive data were collected in the hematology and oncology ward of a tertiary hospital in Japan.ResultsWe recruited 85 patients (with 303 PIVCs), and analyzed 67 patients (with 280 PIVCs). Of these, 118 PIVCs (42%) were inserted during the chemotherapeutic dosing period of the treatment cycle, and 106 (38%), during the rest period. The incidence of cumulative PIVC failure was 43.2% of all analyzed PIVCs (89.97 per 1,000 PIVC days). Of the PIVCs in patients with lymphoma, those inserted during the dosing period were less likely to show PIVC failure (32% vs. 57%,p< .001). Conversely, those inserted after the treatment cycle were more likely to show PIVC failure (22% vs. 7%,p= .002).ConclusionThis study demonstrated that the incidence of PIVC failure in patients with hematological malignancies was unacceptably high. Conceivably, the incidence of PIVC failure varies by the onset time of side effects in the treatment cycle. This should be considered when using PIVCs and selecting optimal vascular access devices for patients with hematological malignancies.